Clinical trial · Interventional
Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma
A Phase I, Multiple Ascending Dose Study of BMS-663513 (Anti CD137) in Combination With Ipilimumab (BMS-734016/Anti-CTLA-4) in Subjects With Unresectable Stage III or Stage IV Melanoma
NCT00803374CI-TRIAL-00005789withdrawnPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine if BMS-663513 administered in combination with ipilimumab to patients with advanced malignant melanoma is safe and tolerable
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Melanoma | Melanoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| AntiCD137 | Drug | — | UNRESOLVED |
| Ipilimumab | Drug | Ipilimumab | ALIAS |
Design
Arms and outcomes
Arms (5)
- type
- EXPERIMENTAL
- label
- 0.1 mg/kg
- interventionNames
- Drug: AntiCD137
- Drug: Ipilimumab
- type
- EXPERIMENTAL
- label
- 0.3 mg/kg
- interventionNames
- Drug: AntiCD137
- Drug: Ipilimumab
- type
- EXPERIMENTAL
- label
- 1.0 mg/kg
- interventionNames
- Drug: AntiCD137
- Drug: Ipilimumab
- type
- EXPERIMENTAL
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically or cytologically confirmed malignant melanoma * Stage III (unresectable) or Stage IV disease which may have been treated with up to one prior cytotoxic chemotherapy and/or up to 3 other therapeutic regimens * Willing to undergo up to 3 biopsies of an accessible lesion Exclusion Criteria: * Active/symptomatic brain metastases * Primary ocular melanoma or primary tumor of unknown origin * Concurrent autoimmune disease * Previous treatment with a CD137 agonist or CTLA-4 inhibitor
References
Publications (0)
Data not yet available
No reference posted for this study.